ETX vs. REDX, POLB, TRX, AREC, SCLP, C4XD, HEMO, SBTX, SAR, and OBD
Should you be buying e-therapeutics stock or one of its competitors? The main competitors of e-therapeutics include Redx Pharma (REDX), Poolbeg Pharma (POLB), Tissue Regenix Group (TRX), Arecor Therapeutics (AREC), Scancell (SCLP), C4X Discovery (C4XD), Hemogenyx Pharmaceuticals (HEMO), SkinBioTherapeutics (SBTX), Sareum (SAR), and Oxford BioDynamics (OBD). These companies are all part of the "biotechnology" industry.
Redx Pharma (LON:REDX) and e-therapeutics (LON:ETX) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their risk, community ranking, profitability, earnings, institutional ownership, analyst recommendations, valuation, dividends and media sentiment.
In the previous week, Redx Pharma had 1 more articles in the media than e-therapeutics. MarketBeat recorded 2 mentions for Redx Pharma and 1 mentions for e-therapeutics. Redx Pharma's average media sentiment score of 0.67 beat e-therapeutics' score of 0.58 indicating that e-therapeutics is being referred to more favorably in the news media.
72.7% of Redx Pharma shares are held by institutional investors. Comparatively, 26.5% of e-therapeutics shares are held by institutional investors. 18.4% of Redx Pharma shares are held by insiders. Comparatively, 59.4% of e-therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.
Redx Pharma's return on equity of -38.75% beat e-therapeutics' return on equity.
Redx Pharma received 25 more outperform votes than e-therapeutics when rated by MarketBeat users. Likewise, 73.56% of users gave Redx Pharma an outperform vote while only 60.09% of users gave e-therapeutics an outperform vote.
Redx Pharma has a beta of -0.53, meaning that its stock price is 153% less volatile than the S&P 500. Comparatively, e-therapeutics has a beta of 0.48, meaning that its stock price is 52% less volatile than the S&P 500.
e-therapeutics has lower revenue, but higher earnings than Redx Pharma. e-therapeutics is trading at a lower price-to-earnings ratio than Redx Pharma, indicating that it is currently the more affordable of the two stocks.
Summary
e-therapeutics beats Redx Pharma on 8 of the 14 factors compared between the two stocks.
Get e-therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for ETX and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding ETX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
e-therapeutics Competitors List
Related Companies and Tools
